Incidence and epidemiology
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western societies. There is an average incidence of 2.7 persons with CLL per 100,000 in the United States. The risk of developing CLL increases progressively with age and is two times higher for men than for women [1••]. Because of its relative indolence, this disease accounts for approximately 0.8% of all cancers and nearly 30% of all leukemias at any point in time.
Environmental factors do not appear to play a major role in the pathogenesis of CLL. In accord with earlier reports, recent analysis [2] of the Swedish Cancer registry with 4,171,175 individuals, contributing 69,639,237 person-years accrued through 1989, did not reveal any association between the development of CLL and exposure to sunlight, pesticides, or solvents.
Viruses also have not been demonstrated to play a direct role in leukemogenesis. Compelling evidence for a relationship between human herpesvirus 7 and development of CLL is lacking [3] . Although infection with hepatitis C has been argued to contribute to development of lymphoid malignancies [4] , there is no direct evidence for involvement of hepatitis C and CLL leukemogenesis. However, transformation with Epstein-Barr virus (EBV) has been associated with some cases of Richter transformation, particularly in patients with profound immune deficiency [5] . Such cases may mimic posttransplant lymphomas that are associated with EBV. It is possible that the lack of immune surveillance in some cases allows for development of EBV-associated lymphoproliferative disease in bystander B cells, similar to that noted in severe combine immune deficiency mice that are reconstituted with blood mononuclear cells from patients with CLL [6].
Cytogenetics, oncogenes, and genetic risk factors
Studies using sensitive fluorescence in situ hybridization, interphase cytogenetic techniques, or improved methods to induce metaphases in CLL [7••] have identified that del 13q14-23.1 is the most common chromosomal abnormality in CLL. This is followed in order by trisomy 12, del 11q22.3-q23.1, del 6q21-q23, and deletions or mutations of the P53 tumor suppressor gene at 17q13 [8•].
The chromosomal region 13q14.3 is frequently deleted in CLL, which might argue that a tumor suppressor gene involved in leukemogenesis is located in this area. Using a battery of six microsatellite markers from 13q12.3-14.3 between the BRACA2 gene and the Rb gene, deletion in 13q14 was detected in leukemia cells of 29 of 78 CLL patients (37%), between D13S153 and the AFMa 301wb5 [9•]. It should be noted that classical cytogenetics appears less sensitive, as such methods detected the 13q14 deletion in leukemia cells from only one out of 69 patients (1%) with whom adequate metaphases were obtained. Review of the clinical performance of patients with deletion in 13q14 suggests that these individuals have a poorer prognosis than do those with normal cytogenetics [9•]. Nevertheless, patients with 13q14 deletions appear to have a better prognosis than do those with trisomy 12 [10•].
Several genes map to 13q14.3, including the first exons of two genes, designated Leu1 and Leu2. Although earlier studies had identified loss of these genes in leukemia cells carrying 13q14.3 deletions, three of 15 cases with 13q14.3 deletions had no detectable mutations in either gene [11] . As such, it appears unlikely that either Leu1 or Leu2 function as a critical tumor suppressor gene involved in CLL leukemogenesis.
Trisomy 12
Trisomy 12 is found in the leukemia cells of about a third of all patients with CLL. One study used sensitive fluorescence in situ hybridization to examine leukemia cells isolated from the lymph node, blood, and marrow of 23 nontreated CLL patients to determine whether cells with trisomy 12 were uniformly distributed [12•]. In 6 of the 23 cases (26%) trisomy 12 was clearly present in all tissues examined. However, in each of these cases, the leukemia cells isolated from the lymph node had a substantially higher proportion of cells with trisomy 12 than did cells isolated from the blood or marrow.
Earlier studies by Gahn et al. [13] identified trisomy 12 in the CD34 + progenitor cells of the marrow or blood in a subset of patients with CLL, suggesting that a pluripotent stem may have incurred somatic mutations that contributed to development of the disease. However, a more recent analysis [14] by this same group at the single cell level indicated that the subset of CLL patients with genetically aberrant CD34+ cells may be extremely rare. As such, it appears that CLL generally is not associated with genetic defects in the pluripotent stem cell.
Instead, trisomy 12 appears to be a genetic defect that is acquired during disease progression [15] . Challenging this notion, however, is a longitudinal study of 41 patients that did not find significant changes in the relative proportion of cells with trisomy 12 during a 4-year period, even in patients with disease progression [16] .
The defect accounting for the association of trisomy 12 and CLL is not known. One study [17] found the marrow and blood leukemia cells of one patient to have an acquired translocation involving chromosomes 6 and 12, t(6;12) (p21.3;q13), implicating band 12q13 as the site of the gene(s) important in this lymphoproliferative B-cell disorder. Nevertheless, classic studies [18, 19] indicated that both the maternal and paternal chromosome 12 is present in leukemia cells with trisomy 12. This makes it less likely that loss of genetic material in this region is responsible for leukemogenesis or disease progression.
Chromosome 11 abnormalities
Approximately 10 to 20% of patients may have leukemia cells with deletions in the long arm of chromosome 11, termed 11q - [20] . These patients tend to be younger in age (less than 55 years) and to have more aggressive disease progression than those without such genetic changes. Furthermore, the leukemia cells of such patients may express lower levels of surface CD11a/CD18, CD11c/CD18, CD31, CD48, and CD58 than do CLL cells from patients without 11q -, arguing that such cells may have a distinctive biology [21•].
Chronic lymphocytic leukemia B cells also can have translocations or deletions involving 11q13, a region that contains the tumor suppressor gene associated with multiple endocrine neoplasia syndrome type I (MEN1) [22] . However, deletions on chromosome 11 more commonly cluster between 11q14-24, particularly at 11q22.3-q23.1, in a region defined by yeast artificial chromosome (YAC) clones 801e11, 975h6, and 755b11 [20, 23] . The region represented by YAC 755b11 (1.6 Mb in size) was involved in all cases with deletions, supporting the hypothesis that this region might contain a novel gene of pathogenic importance to CLL. A more distal region represented by YAC 785e12 (760 kb in size) was deleted frequently and specifically.
Potential tumor suppressor genes within this region include ATM (mutated in ataxia telangiectasia) and RDX (Radixin). Radixin (RDX) has homology with the neurofibromatosis type-2, tumor suppressor gene (NF2). ATM, on the other hand, is the gene mutated in ataxia telangiectasia. Upon DNA damage, the normal gene plays an important role in the activation of the tumor suppressor gene product P53, leading to cell-cycle arrest and DNA repair [24] . The ATM gene has been noted to be lost through deletion or mutation in leukemia cells of patients with relatively aggressive disease [20,25,26,27••,28,29•]. Some patients with CLL carry one defective copy of this gene in the germ line DNA, suggesting that mutations in ATM may be involved in the pathogenesis of aggressive CLL [27••,30••].
Chromosome 6 abnormalities
Another recurring chromosome abnormality involves the short arm of chromosome 6, but the genes altered have not been identified [31] . The most frequent abnormalities on chromosome 6 result in deletions at 6q25-27, this being detected in 21% of patients with CLL [32•]. Patients with leukemia cells that have deletions in this region may be prone to having higher proportions of blood prolymphocytes and more aggressive clinical disease.
Other genetic abnormalities p53 Abnormalities
Unbalanced translocations involving chromosome 17p, where the P53 tumor suppressor gene is located, are rarely noted in CLL. However, one study of advanced cases noted unbalanced translocations involving 17p in 14 out of 123 (11%) cases [33•]. In all cases, translocations led to a monosomy 17p and to a P53 monoallelic deletion. The association of P53 gene defects with advanced, refractory disease and Richter's transformation [34] , argues that such defects may contribute to disease progression and genetic instability, leading to greater resistance to chemotherapy [35] .
Immunoglobulin genes
Cases of CLL may be segregated on the basis of whether the leukemia cells express nonmutated versus mutated immunoglobulin (Ig) variable region genes (V genes) [36••,37••]. The extent to which V genes are mutated does not vary within any one leukemia cell population [38] , even when examined during a period of years [39] . Leukemia cells that express nonmutated Ig V genes more often may have trisomy 12 and atypical morphology than those that expressed mutated Ig V genes, which in turn more frequently tend to have abnormalities involving 13q14 [40] . Furthermore, patients with leukemia cells that express mutated Ig V genes appear to have a more indolent clinical course than patients with leukemia cells that express nonmutated Ig V genes [36••,37••].
The leukemia cells from approximately 7% of CLL patients, however, may lack immunoglobulin heavy chain allelic exclusion [41] . Leukemia cells lacking allelic exclusion express at least two different immunoglobulin heavy chains encoded by each immunoglobulin allele. Some leukemia cells have been found to express both mutated and nonmutated Ig V genes simultaneously [42] . This finding complicates the use somatic mutation as a means to segregate distinct leukemia subtypes, at least for this subgroup of patients.
CD79b
One study analyzing 27 unselected cases of CLL found that more than 75% had low to absent expression of CD79b, an important accessory protein required for expression and signal transduction of surface immunoglobulin [43] . Although mutations affecting the signal transduction domain of this molecule were implicated to account for the altered expression in CLL, analyses of additional cases by other investigators failed to reveal structural mutations in this domain [42,44•]. Instead, alternative splice of the CD79b gene was found responsible for the reduced expression of surface immunoglobulin that is associated with the CLL phenotype [44•]. As normal B cells also can express this alternative splice variant of CD79b, the peculiar posttranscriptional regulation of CD79b seen in CLL might be a reflection of its cytogenesis rather than a factor involved in leukemogenesis.
Biology Phenotype
In nearly all cases, the leukemia cells express CD5 along with CD19, CD23, and low levels of CD20 [45] . Leukemia cells that are CD5 negative generally are found to represent lymphoproliferative diseases other than CLL upon more rigorous phenotypic and pathologic analyses.
The neoplastic B cells in mantle cell lymphoma express many of the same surface antigens as do CLL B cells, including CD5. However, in contrast to CLL B cells, mantle cell lymphoma cells generally do not express CD23. Mantle cell lymphoma cells also tend to express higher levels of CD79a than do CLL cells [46].
Medullary involvement
The marrow is invariably involved with leukemia cells. The pattern of marrow involvement has predictive value. A diffuse replacement of the marrow carries a worse prognosis than a nodular or interstitial pattern. As such, a marrow biopsy is helpful in staging patients and in evaluating the response to therapy [47] .
Chemokines may play a central role for lymphocyte trafficking and homing to the marrow. CLL cells are capable of transendothelial migration [48] . As transendothelial migration induces lymphocyte shedding of L-selectin and CD23, the high serum levels of soluble L-selectin and CD23 observed in CLL may be generated by leukemia cell trans-endothelial migration. CLL B cells express functional CXCR4 receptors for the stromal cell-derived factor-1 (SDF-1) and display chemotaxis toward this chemokine [49••]. Because marrow stromal cells secrete SDF-1, this may account for the observation that CLL cells invariably are present in the marrow.
Cell kinetics
There is a small pool of proliferating cells. In the spleen, proliferation of CLL cells occurs preferentially in the white pulp zones, even in cases in which both the white and red pulp are extensively infiltrated [50]. However, most blood CLL cells are not in the cell mitotic cycle (ie, they are in G 0 ), as determined by the extremely low incorporation rate of 3 H-thymidine by leukemic lymphocytes [51] or by flow cytometric analyses for newly synthesized DNA [52] . The low proportion of proliferating cells suggests that the lifespan of CLL lymphocytes is quite long. Consistent with this, human CLL B cells can survive for many weeks after transfer into mice with severe combined immune deficiency [53] .
Resistance to apoptosis
Chronic lymphocytic leukemia is an accumulative disease of long lived leukemia B cells that express high levels of the anti-apoptotic protein bcl-2. Bcl-2 protein levels can be assessed reproducibly by immunocytochemistry, flow cytometry, or immunoblotting [54] . Although the levels of leukemia cell expression of bcl-2 did not correspond to the extent of tumor mass, higher levels were associated more frequently with aggressive clinical disease or resistance to chemotherapy [55•,56,57]. Antisense oligonucleotides to BCL-2 can downmodulate expression of mRNA encoding this anti-apoptotic protein in CLL cells in vitro [55•], suggesting that such oligonucleotides may be useful therapeutic agents, either alone or in combination with chemotherapy.
In addition, the neoplastic B cells of patients with CLL also characteristically express high levels of another antiapoptotic protein, bcl-x L , and low levels of the pro-apoptotic protein bax or bcl-x S [58]. Bcl-2 and bax proteins form homodimers and heterodimers that influence the susceptibility to apoptosis. Moreover, patients who are resistant to treatment with chlorambucil have been noted to have leukemia cells that contain a high ratio of bcl-2 to bax. Furthermore, leukemia cells from patients who respond to this drug apparently upregulated their expression of bax within hours after exposure to chlorambucil, whereas leukemia cells from resistant patients failed to modulate bax expression in response to this drug [59]. However, it remains to be seen whether testing for induction of bax by chlorambucil in vitro can prospectively identify patients who should be responsive to chemotherapy.
Interactions with stroma may enhance leukemia cell resistance to apoptosis. CLL cells express high levels of the α 4 β 1 integrin that can serve as a receptor to fibronectin and that also facilitates cell-to-cell adhesion and leukocyte migration [60] . Chronic lymphocytic leukemia cells cultured with fibronectin, or the H89 fragment containing the high affinity ligand CS-1, were found to have increased ratios of Bcl-2/Bax and survival times that were greater than that of leukemia cells cultured alone. Such host-leukemia cell interactions may account for the often noted discordance between the results of in vitro chemosensitivity testing and the clinical response to chemotherapy. 
Therapy Prognostic markers
There are no established cures for CLL, and spontaneous remissions are extremely rare [70] . Nevertheless, the prognosis can vary substantially between different patients, depending upon clinical stage and the presence or absence of disease features that have been associated with disease progression or a more adverse clinical outcome. In the patient with CLL, clinical condition, stage, and prognosis should be factored into the decision of when to treat. In one multi-center study [71•], the 10year survival rate was slightly worse for early-stage patients treated with immediate chemotherapy than for patients with early-stage disease whose treatment with chemotherapy was deferred (44% versus 47% survival; difference = -3%; 95% confidence interval [CI] = -10% to 4%). As such, staging in CLL continues to play an important role in defining when to initiate therapy.
In addition to the widely accepted staging systems of Rai and Binet, there are additional indicators that can help identify high risk patients who may benefit from closer follow-up or early therapy. Progressive disease is associated with the following characteristics: 1) a lymphocyte doubling time of less than 12 months; 2) elevated serum β 2 -microglobulin; 3) high serum levels of soluble CD23 (sCD23); 4) a blood leukocyte count of more than 30 × 10 9 /L; 5) atypical morphology [72]; 6) elevated serum thymidine kinase levels [73]; 7) leukemia-cell expression of the low affinity interleukin-2 (IL-2) receptor (CD25); and 8) any complex karyotypic abnormalities, including trisomy 12 [74] . A more adverse clinical course also has been associated with leukemic cells that express CD38 [37••] or nonmutated
In addition, progressive disease more typically is associated with a greater suppression of T-cell function and a more marked decline in serum IgA [75] . After adjusting for the impact of the other variables, atypical morphology, high leukocyte count, short lymphocyte doubling time, high serum levels of soluble CD23 (sCD23), elevated serum β 2 microglobulin, and enlargement of one or more lymph nodes sites remain as significant adverse prognostic markers. Hypercalcemia is rare in patients with CLL [76] and may indicate Richter's transformation [77] .
Although patient age had been considered an independent prognostic factor, a study [1••] from the United States National Cancer Data Base revealed that the 5year relative survival was 69.5%, 72.2%, 63.1%, and 41.7% for patient groups younger than 40 years of age, 40 to 59, 60 to 79, and more than 80 years of age, respectively, indicating that the 5-year survival does not vary significantly between these different age groups. As such, it appears that CLL, and not comorbid disease, caused the greatest percentage of deaths, even among the aged.
Although both younger and older patients have a similar overall median survival probability, another study [78] found these groups had different distributions of causes of deaths. Deaths unrelated to CLL, and secondary malignancies, predominated in the older age group, whereas the direct effects of leukemia were prevalent in the younger age group. At diagnosis, younger and older patients alike displayed a similar distribution of clinical features, except for a significantly higher male-to-female ratio in younger patients (2.85 versus 1.29; P < .0001). Both groups had an elevated rate of second malignancies (8.3% versus 10.7%), whereas the occurrence of Richter syndrome was significantly higher in younger patients (5.9% versus 1.2%; P < 0.00001). Two subsets of young patients under age 55 with CLL who had a different prognostic outcome could be identified. One group, comprising 40% of the patients under age 55, had long lasting stable disease without treatment and an actuarial survival probability of 94% at 12 years after diagnosis. The remaining patients had progressive disease and a median survival probability of 5 years after therapy [78] .
A key feature of patients with the more adverse prognosis is evidence for disease progression [79] .
Although many hematologists still use chlorambucil for initial treatment of patients with CLL, increasing numbers of practitioners use fludarabine as front-line therapy for CLL [80] . When given as a 30 minute intravenous infusion at a dose of 25 mg/m 2 daily for 5 days at four week intervals, this drug has been shown, in multicenter clinical trials, to induce hematological complete and partial responses in a high percentage of patients. Also, fludarabine given intravenously has been found effective in the treatment of leukemic cell infiltration of the central nervous system [81] . An oral form of fludarabine has been developed that has good bioavailability and low intra-individual variation in its pharmacodynamics [82], making it feasible to consider alternative dosing regimens.
One group [83,84] has used the differential staining cytotoxicity (DiSC) assay to assess the sensitivity or resistance to fludarabine of CLL cells in vitro. They noted that the cytotoxic activity of fludarabine scored using this assay had a significant correlation with the clinical response to therapy. As such, this assay could potentially identify patients who should receive alternative forms of treatment and thus be spared from any fludarabine-induced toxicity. It remains to be seen, however, whether the DiSC assay can prospectively segregate responders versus non-responders to fludarabine in multicenter clinical trials.
Although cases of autoimmune hemolytic anemia and Evan's syndrome have been reported flowing treatment with fludarabine [85] , this drug also has been successfully used in the treatment of autoimmune disorders associated with CLL, such as acquired factor VIII inhibitor [86] . Indeed, treatment with fludarabine can induce prolonged immune suppression and depletion of CD4 T cells, leading to an increased risk for opportunistic and nosocomial infections. Nevertheless, the use of fludarabine or related purine analogs has not contributed to an increased risk for secondary malignancies in CLL [87] .
Combination chemotherapy with fludarabine
Because treatment of patients with fludarabine has not been shown to improve overall survival, several clinical trials testing this drug in combination with other chemotherapeutic agents have been conducted. Combinations of fludarabine, at 25 to 30 mg/m 2 daily for 3 days, with mitoxantrone, at 10 to 50 mg/m 2 given on day 1, were evaluated in patients with CLL who did not respond well to alkylators, and was found to have overall response rates that were not significantly different from treatment regimens of fludarabine as a single agent [88] . Cisplatin, administered at 100 mg/m 2 via continuous intravenous infusion during a 4-day period, has been used in combination with fludarabine given at 30 mg/m 2 via bolus intravenous infusion on days 3 and 4 of a 28-day cycle [89] . These two drugs alone, or in combination with cytosine arabinoside at 500 mg/m 2 on day 4 of the cycle, did not appear to offer significant benefit over that of single agent fludarabine in the treatment of patients who did not respond well to alkylating agents. However, combinations of fludarabine, at 30 mg/m 2 daily for 3 days, and cyclophosphamide, at 300 mg/m 2 daily for 3 days, resulted in favorable clinical responses in 12 of 13 patients who were extensively pretreated [88] . A more recent study using fludarabine at 25 mg/m 2 /d in combination with cyclophosphamide 250 mg/m 2 /d for 3 days, repeated every 4 weeks, resulted in similar clinical response rates but reduced myelotoxicity [90] . Nevertheless, treatment at this dose still resulted in increased myelotoxicity over that of single agent fludarabine and failed to eradicate the leukemia cell clone.
In vitro studies on drug sensitivity have examined other fludarabine-based combinations. Mafosfamide, the active form of cyclophosphamide in vitro, also synergistically increased the cytotoxicity of fludarabine on CLL cells studied (P <.01), which supports the notion that fludarabine, in combination with cyclophosphamide or its derivatives, may be effective in the treatment of CLL [91] . Loxoribine, a guanine ribonucleotide, has been found to increase the cytotoxic activity of fludarabine, with or without mafosfamide, on CLL cells in vitro [92] . Gemcitabine also has been noted to increase fludarabine-induced cytotoxicity of CLL cells in vitro, especially when lower doses of gemcitabine were combined with fludarabine [93] .
Cladribine (2-chlorodeoxyadenosine)
Cladribine is another purine analog with activity in treating CLL. At a dosage of 0.12 mg/kg daily for 5 consecutive days repeated monthly for 6 months (median 3), cladribine induced complete and partial responses of about 70% in previously nontreated patients with CLL [94, 95] . Overall response rates of about 50% are typically seen in patients who do not respond well to alkylating agents [95] . The differential staining cytotoxicity (DiSC) assay may be able to predict which patients will respond to cladribine [96] , thus potentially sparing those patients who would not respond the toxicity of cladribine therapy. However, as noted above, the ability of the DiSC assay to predict which patients will respond to treatment remains to be tested prospectively in multicenter clinical trials.
Cladribine also is being considered for use in combination with mitoxantrone and dexamethasone (CMD) in view of activity in lymphoma patients who had refractory or relapse disease [97] . Similar to its activity with fludarabine, cyclophosphamide, or its derivatives (eg, mafosfamide or 4hydroxycyclophosphamide), apparently can enhance the cytotoxicity of cladribine for CLL cells in vitro [98] .
Other agents Glucocorticoids
Glucocorticoids can be effective as single agents in CLL, especially for patients with autoimmune hemolytic anemia or immune thrombocytopenia. Even for nonautoimmune manifestations, prednisone, as a single agent, can control the disease temporarily in a small percentage of patients. Generally, prednisone is given orally at a dosage of 40 to 60 mg/day for 1 week, then tapered and stopped after another week. Thereafter, prednisone is given every month for 5 days at 60 mg/day. Partial responses in patients refractory to alkylating agents and purine analogs may be achieved in a larger number of patients by treatment with intravenous methylprednisolone at 1 gm/m 2 /day for 5 days at monthly intervals for 7 months [99] . Concomitant therapy with H 2 antagonists and prophylactic antibiotics can reduce the rate of treatment-related complications, which also include fluid retention and hyperglycemia.
Melarsoprol
Melarsoprol, an organic arsenical compound used for treatment of trypanosomiasis, was noted to effect downmodulation of BCL-2 and induce apoptosis of CLL cells in vitro [100] . Because of this, a clinical trial was conducted in which patients received escalating intravenous doses daily for 3 days, repeated weekly for 3 weeks, with doses of 1 mg/kg on day 1, 2 mg/kg on day 2, and 3.6 mg/kg on day 3 and on all days thereafter, up to a maximum daily dose of 200 mg [101] . However, treatment was associated with significant central nervous system toxicity and limited clinical benefit. Depsipeptide Depsipeptide (FR901228) is a novel agent entering clinical trials that has selective in vitro activity against resistant leukemia cell lines [102•]. Moreover, this agent apparently induces favorable decreases in p27 and the ratio of the bcl-2 to bax expressed by CLL cells in vitro.
Bryostatin 1 (bryo 1)
Bryostatin 1 has been proposed as an agent that can enhance the sensitivity of CLL cells to chemotherapeutic agents, such as the purine analogs fludarabine or cladribine [103] . However, bryostatin also may induce expression of anti-apoptotic proteins such as Mcl-1, potentially leading to enhanced resistance to chemotherapy [104] . Nevertheless, treatment with bryostatin apparently could enhance the cytotoxic activity of fludarabine in vivo when tested in a xenograft model of mice with severe combined immune deficiency reconstituted with human CLL cells [105].
Lactacystin
Lactacystin is an inhibitor to the ubiquitin-proteasome pathway involved in antigen processing that also has been found capable of inducing CLL cells to undergo apoptosis in vitro at drug concentrations that had no effect in normal cells [106•]. As such, this agent is being considered for use alone or in combination with radiation or chemotherapy for the treatment of CLL.
Monoclonal antibodies Rituximab
Rituximab (IDEC-C 2 B 8 ) is humanized monoclonal antibody (mAb) specific for human CD20 that can induce responses in nearly half of patients treated who have relapsed follicular lymphoma [107,108]. However, CLL B cells express nearly 10-fold lower levels of CD20 than most lymphoma cells and may be less sensitive to treatment with Rituximab.
Some patients have experienced tumor-lysis syndrome following treatment with Rituximab [109]. Moreover, patients with leukemia cell counts exceeding 50 × 10 9 /L at the time of treatment have been noted to experience a severe cytokine-release syndrome secondary to release of tumor necrosis factor-α and IL-6 [110, 111] . Elevated cytokine levels during treatment were associated with clinical symptoms, including fever, chills, nausea, vomiting, hypotension, and dyspnea. Lymphocyte and platelet counts dropped to 50% to 75% of baseline values within 12 hours after the onset of the infusion. Simultaneously, there was a fivefold to 10-fold increase of liver enzymes, d-dimers, and lactate dehydrogenase, as well as a prolongation of the prothrombin time. This complication may be mitigated by use of a fractionated dosing schedule with infusion of 50 mg rituximab on day 1, 150 mg on day 2, and the rest of the 375 mg/m 2 dose on day 3 [110] . Nevertheless, treatment of CLL patients with Rituximab should be performed in the context of a clinical trial.
CAMPATH-1H
CAMPATH-1H (Cambridge Pathology-1 Humanized) is a genetically engineered mAb that contains the variable region of CAMPATH-1, a CD52 mouse mAb, and the heavy and light chain constant regions of human IgG 1 and kappa, respectively. This antibody binds to a surface antigen present on most lymphocytes, including CLL B cells, and can induce complement-mediated and antibody-dependent cell cytotoxicity. In one study, patients who did not respond well to chemotherapy were given intravenous infusions of 30 mg CAMPATH-1H three times a week for 12 weeks [112] . Of the 29 patients to receive such therapy, 38% experienced a partial remission and 4% experienced a complete remission with median response duration of 12 months. However, CAMPATH-1H appears most effective in eliminating leukemia cells from the blood and bone marrow, and has relatively little effect on reducing the size of enlarged lymph nodes and spleen [80] .
Treatment with CAMPATH-1H causes marked Tcell depletion and immune deficiency. Patients treated with CAMPATH-1H routinely are given prophylactic antibiotics to reduce the incidence of opportunistic infection. In some cases, marked T-cell depletion has been associated with development of systemic autoimmune disease, such as immune thrombocytopenia [113] .
Lym-1
Lym-1 is an IgG 2a mouse mAb specific for human B cells that has been used in the radioimmune therapy of CLL [114, 115] . Conjugated with I 131 , this mAb has been used in phase I and II trials in which patients received I 131 -Lym-1 in escalating amounts from 1.48 GBq/m 2 to 3.7 GBq/m 2 (40 to 100 mCi/m 2 ) [116] . For patients with splenomegaly, most of the administered radiolabeled antibody localized to the spleen and did not distribute uniformly through other lymphoid tissue. Although the treatment was well tolerated, the efficacy of this approach in CLL appears lower than that noted for non-Hodgkin's lymphoma.
Cytokines
Interleukin-6 (IL-6) is a B-cell growth factor that has been used with the intent to induce leukemia cell proliferation before administration of cytotoxic therapy [117] . However, this study did not find evidence that administration of human recombinant IL-6 (rhIL-6) induces leukemia cell proliferation in vivo. However, this study observed that rhIL-6 did induce leukemia cells to express higher levels of CD20, an effect that subsided after cessation of therapy. This raises the possibility that treatment with rhIL-6 may enhance the therapeutic efficacy of mAb to CD20, such as Rituximab.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) may increase the blood granulocyte levels, leading to improved resistance against opportunistic infections [118] . Nonetheless, such treatment appears most effective in patients who are recovering from chemotherapy-induced myelosuppression.
Stem cell transplantation
Allogeneic transplantation has resulted in prolonged remissions in young patients with relapsed and refractory CLL, but is associated with high treatment-related morbidity and mortality [119] . Treatment of patients with combination chemotherapy followed by autologous stem cell transplantation can induce molecular complete remissions, as assessed by the polymerase chain reaction for clonal immunoglobulin gene rearrangement [120] [121] [122] . Although direct procedure-related mortality in the first 100 days is low, some studies [122] report a relatively short median survival from the time of transplantation. Although this may be a reflection of the relatively poor initial prognosis of patients undergoing stem cell transplantation, clinical trials are necessary to establish whether this form of treatment can prolong survival in but a selected subset of patients with disease that is highly sensitive to chemotherapy. 
Gene therapy
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Conclusions
Research over the past few years has provided insight into the genetic factors that may contribute to the development or progression of CLL. Recent studies suggest that CLL may be a heterogeneous disorder, with at least two major subgroups. These subgroups may be distinguished by their associated cytogenetic abnormalities, expression of mutated versus non-mutated immunoglobulin genes, surface-antigen phenotype, morphology, or tendency toward disease progression. Furthermore, additional clinical features have been found that are associated with progressive disease. Recognition of these features may compliment standard clinical staging criteria in defining prognosis or when best to initiate therapy. Additional research and distinct clinical subsets and whether the newly identified prognostic features have independent predictive value. Although there is no established curative therapy for patients with CLL, many new treatments are under investigation. These include combination chemotherapy, novel drugs, biologics, stem cell transplantation, and gene therapy. Some of these may provide more effective, and potentially curative, therapy for patients with this disease.
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